Cisplatin hearing loss data
WebMar 29, 2024 · This hearing disorder results from temporary or permanent inner ear dysfunction, typically causing bilateral high-frequency sensorineural hearing loss that progresses to lower frequencies with continued exposure. 3 The risk of permanent bilateral sensorineural hearing loss and tinnitus can occur both during treatment and long-term … WebAtorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer Latest version (submitted April 11, 2024) on ClinicalTrials.gov A study version is represented by a row in the table. Select two study versions to compare. One each from columns A and B.
Cisplatin hearing loss data
Did you know?
WebApr 13, 2024 · Spankovich et al. showed a reduced cisplatin-related hearing loss by cold water irrigation in guinea pigs ( Spankovich et al., 2016 ). In an alternative rodent experiment, the otoprotective effect of hypothermia applied through a custom-made cooling device was evaluated in a cochlea implantation situation. WebDec 11, 2024 · It is used for the treatment of a variety of cancers such as cervical, breast, stomach, prostate, bladder and oesophageal, to name a few. However due to its expansive toxicity profile, patients receiving cisplatin can experience high frequency hearing loss, a side effect known as ototoxicity.
WebJun 1, 2024 · Overall, for all cancers treated with cisplatin, the incidence of hearing loss is about 50%. But some specific cancers, especially children who have cancers in very early childhood—say, younger than 5 years old—tend to have a more severe cisplatin-induced hearing loss and at a higher incidence. WebJul 2, 2024 · Caffeine pre-treatment further reduced wave I and II amplitudes, suggesting worsening of cisplatin-induced hearing loss. The data is plotted as mean ± SEM (n ≥ 6). Asterisks, * p < 0.05 vs....
WebOct 6, 2024 · Cisplatin belongs to a group of platinum-based chemotherapy drugs. Research has suggested that hearing loss may result from damage caused by the … WebJan 4, 2024 · BACKGROUNDCisplatin is widely used to treat adult and pediatric cancers. It is the most ototoxic drug in clinical use, resulting in permanent hearing loss in …
WebJan 1, 2024 · The benefits of atorvastatin to the incidence of a CTCAE-defined hearing loss were generally consistent across all subgroups (Figure 3). Overall, 48.8% (156 of 320) of …
WebCisplatin-induced early-onset ototoxicity is linked to hearing loss. The mechanism by which cisplatin causes ototoxicity remains unclear. The purpose of this study was to … east meredith ny 13757WebCisplatin is one of the most effective chemotherapy agents, used in just under half of pediatric cancer cases. Permanent hearing loss is a common side effect of this … culture of gujarat in hindiWebApr 6, 2016 · Significance statement: Cisplatin is a widely used chemotherapeutic agent for the treatment of solid tumors. Its use results in significant and permanent hearing loss, for which no US Food and Drug Administration-approved treatment is currently available. culture of greater accra regionWebTaking a genome-wide association study approach, we identified inherited genetic variations in ACYP2 associated with cisplatin-related ototoxicity (rs1872328: P = 3.9 × 10(-8), hazard ratio = 4.5) in 238 children with newly diagnosed brain tumors, east meridian prison msWebMar 15, 2024 · Cisplatin can cause hearing loss in up to 60% of the treated population, leading to significant impact on QoL. Data from a population-based longitudinal study of age-related hearing impairment (N = 2,688) showed that 28% of adults age 53-97 years … east mersea bus timetableWebFeb 1, 2024 · Tell you doctor right away if you have blood in urine, change in frequency of urination or amount of urine, difficulty in breathing, drowsiness, increased thirst, loss of appetite, nausea or vomiting, swelling of the feet or lower legs, or weakness. east meridian parking facilityWebFeb 28, 2024 · One of the main problems in chemotherapy using platinum drugs as anticancer agents is the resistance phenomenon. Synthesizing and evaluating valid alternative compounds is challenging. This review focuses on the last two years of progress in the studies of platinum (II)- and platinum (IV)-based anticancer complexes. In … culture of health blog